Genomatix to Provide Data Analysis for NGS-Based Cancer Prognostic Marker Discovery Effort | GenomeWeb

Genomatix Software, the Center for Prostate Disease Research at the Uniformed Service University of the Health Sciences, and the Henry M. Jackson Foundation for the Advancement of Military Medicine have inked a Cooperative Research and Development Agreement that extends ongoing research efforts in prostate disease research.

Genomatix said this week that the joint research will aim to differentiate patients with favorable versus poor prognosis at the time of their diagnosis as well as to determine primary treatment using definitive genetic markers.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.